Cigna Group (NYSE:CI) is drawing broad analyst support, with twenty-one research firms rating the health services company. Sixteen analysts have assigned buy ratings, four have issued hold ratings, and one has given a strong buy rating, according to MarketBeat data. The consensus twelve-month price objective stands at $336.20, signaling potential upside from recent trading levels.

Recent analyst activity reflects mixed sentiment on the insurer. Sanford C. Bernstein upgraded Cigna from "market perform" to "outperform" in March, raising its price target from $307 to $358. Barclays increased its price objective from $303 to $310 and assigned an "overweight" rating. Wall Street Zen upgraded the stock from "hold" to "buy" in early February, while Zacks Research upgraded it from "strong sell" to "hold" in January. Robert W. Baird set a $337 price objective on the company.

Positive momentum stems partly from first-quarter results. Cigna reported earnings per share of $7.79, exceeding the consensus estimate of $7.60, and generated revenue of $68.52 billion against expectations of $66.29 billion. The company's Evernorth unit delivered strong performance. Management raised its full-year 2026 adjusted earnings per share guidance to at least $30.35, bolstering confidence in the valuation. Royal Bank of Canada raised its price target to $337 while maintaining an "outperform" rating.

However, headwinds persist. Cigna announced plans to exit the Affordable Care Act individual exchange business in 2027, affecting approximately 369,000 members. Analysts also flagged rising pharmacy costs and complexity in its pharmacy benefit management operations as potential margin pressures, even as Evernorth expands. Some institutional investors have been repositioning holdings and insider sales have occurred in recent weeks, signals that some market observers monitor closely.

On the capital front, Cigna declared a quarterly dividend of $1.56 per share, payable June 18th to shareholders of record on June 4th. The annualized dividend yield stands at 2.2%, with a payout ratio of 28.13%. The stock trades with a price-to-earnings ratio of 12.00 and a market capitalization of $74.62 billion. Institutional investors hold approximately 87% of outstanding shares.